Mirxes, a Singapore-headquartered developer of RNA-based tests for the early detection of cancer and other diseases, said this week that it has recently signed two agreements that will help advance the company's commercial push into China and Indonesia.
The Alzheimer’s disease blood test developer C2N Diagnostics has released a new version of its screener for beta amyloid proteins, and it’s gearing up for a nationwide rollout as public hopes rise for treatments that may make some headway against the condition.
A new blood test is being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients as well as the healthcare system.
Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years before dementia symptoms arise.
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.
Qiagen on Thursday announced a systematic review and publication of the clinical relevance of test values from its QuantiFeron-TB Gold Plus TB1 and TB2 blood collection tubes.
A blood test identified patients with a treatable neurometabolic disease in a prospective trial, suggesting that it can be used to improve diagnosis of a condition that is currently detected using an invasive procedure.
Berry Genomics recently announced that it will acquire NeoGenomics, a US-based blood testing company, for US$2.4 billion to further strengthen its oncology testing business.
Naveris said Wednesday that Mayo Clinic began a Phase II trial of its circulating tumor DNA blood test, NavDx, to guide treatment for patients with HPV-driven head and neck cancer.
In a new study looking at the long-term effects of hospitalized patients who have acute kidney injury, Johns Hopkins Medicine researchers found that higher levels of certain biomarkers in urine and blood can predict a patient’s risk of developing chronic kidney disease.
✔ All (33)
✔ Press release (0)
✔ Industry news (33)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.